# US 2013/0252897 A1 · Methods and Compositions Regarding Polychalcogenide Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252897 A1
- Document ID: US20130252897A1
- Status: Published application
- Kind: A1
- Application number: 13/619,933
- Filed: 2012-09-14
- Published: 2013-09-26
- Earliest claimed: 2007-06-25
- Assignees: Fred Hutchinson Cancer Research Center
- Inventors: Mark B. Roth; Mike Morrison
- Web page: https://patentgrep.com/patent/US20130252897A1

## CPC

- C07K 17/14: Peptides being immobilised on, or in, an inorganic carrier
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 38/063: {Glutathione}
- A61K 38/38: Albumins
- A61K 38/385: {Serum albumin}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns the use of polychalcogenide compositions on cells, tissue, organs, and organisms to enhance their survivability. It includes compositions, compounds, methods, articles of manufacture and apparatuses for enhancing survivability and for protecting them from or treating them for injury or damage. In specific embodiments, there are also therapeutic methods and apparatuses for hypoxic/ischemic injury, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the polychalcogenide compositions described.

## Claims

### Claim 1

A polysulfide composition comprising (i) a peptide or a protein and (ii) a polychalcogenide salt, wherein the polychalcogenide salt is further defined as a compound of formula (I):
Z2Sn (I)
wherein Z is a counterion and n is a number or average number ranging from 1-35, wherein the number or average number is an integer or non-integer ranging from 1-35.

### Claim 2 (depends on 1)

The polysulfide composition of claim 1, wherein the peptide or the protein is a glutathione or albumin, respectively.

### Claim 3 (depends on 2)

The polysulfide composition of claim 2, wherein the glutathione is oxidized glutathione or reduced glutathione.

### Claim 4 (depends on 1)

The polysulfide composition of claim 1, wherein the counterion is an alkali metal ion.

### Claim 5 (depends on 1)

The polysulfide composition of claim 1, wherein n represents an average number of 5.5.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the polysulfide composition of claim 1 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the polysulfide composition is an aqueous solution.

### Claim 8 (depends on 1)

A method of preparing an aqueous solution comprising the polysulfide composition of claim 1, comprising:
(a) mixing an aqueous solution comprising the peptide or the protein with
(b) a polychalcogenide salt, wherein the polychalcogenide salt is further defined as a compound of formula (I):
Z2Sn (I)
wherein Z is a counterion and n is a number or average number ranging from 1-35, wherein the number or average number is an integer or non-integer ranging from 1-35.

### Claim 9 (depends on 8)

The method of claim 8, wherein the polychalcogenide salt is further defined as a liquid solution formed from mixing two parts sodium sulfide nonahydrate with one part solid S8.

### Claim 10 (depends on 8)

The method of claim 8, wherein the peptide or the protein is a glutathione or albumin, respectively.

### Claim 11 (depends on 9)

The method of claim 9, further comprising diluting the liquid solution formed from mixing two parts sodium sulfide nonahydrate with one part solid S8 with HCl.

### Claim 12 (depends on 8)

The method of claim 8, further defined as the following:
(a) mixing an aqueous solution comprising a mixture of albumin and a glutathione with
(b) a liquid solution formed by mixing two parts sodium sulfide nonahydrate with one part solid S8.

### Claim 13 (depends on 12)

The method of claim 12, wherein the ratio of albumin to total glutathione in (b) ranges from about 2:1 to about 3:1.

### Claim 14 (depends on 1)

A method comprising providing the polysulfide composition of claim 1 to a subject, wherein the subject has or is at risk for a hypoxic/ischemic injury, trauma, hyperproliferative disease or condition, neurodegenerative disease, or transplant rejection.

### Claim 15 (depends on 14)

The method of claim 14, wherein the hypoxic/ischemic injury, hemorrhagic shock, hyperproliferative disease or condition, neurodegenerative disease, inflammatory disease, transplant rejection, or autoimmune disease or condition is prevented or treated.

### Claim 16 (depends on 1)

A method for preventing or treating damage in a subject comprising providing to the subject an effective amount of the polysulfide composition of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the damage is from trauma caused by an external physical source.

### Claim 18 (depends on 17)

The method of claim 17, wherein the trauma is surgery.

### Claim 19 (depends on 16)

The method of claim 16, wherein the subject has or is at risk for a hypoxic/ischemic injury, hyperproliferative disease or condition, neurodegenerative disease, or transplant rejection.

### Claim 20 (depends on 19)

The method of claim 19, wherein the subject has or is at risk for hypoxic/ischemic injury.

### Claim 21 (depends on 20)

The method of claim 20, wherein the hypoxic/ischemic injury is heart attack, cardiac surgery with cardio-pulmonary bypass, stroke, hematologic shock, or hemorrhagic shock.

### Claim 22 (depends on 20)

The method of claim 20, wherein the injury involves hemorrhaging.

### Claim 23 (depends on 19)

The method of claim 19, wherein the injury or disease is associated with a reduction in metabolism or temperature of the subject.

### Claim 24 (depends on 19)

The method of claim 19, wherein the subject is provided with the polysulfide composition before, during, and/or after, or any combination thereof, the injury or onset or progression of the disease or condition.

### Claim 25 (depends on 24)

The method of claim 24, wherein the subject is provided with the polysulfide composition in an amount and for a time that protects the subject from damage or death resulting from the injury or the onset or progression of the disease.

### Claim 26 (depends on 16)

The method of claim 16, wherein the subject is provided with the polysulfide composition under hypoxic or anoxic conditions or prior to exposure to hypoxic or anoxic conditions.

### Claim 27 (depends on 16)

The method of claim 16, wherein the polysulfide composition is provided to the subject as comprised in or as a liquid.

### Claim 28 (depends on 16)

The method of claim 16, wherein the subject is provided the polysulfide composition for a period of time between about 30 seconds and 30 days.

### Claim 29 (depends on 16)

The method of claim 16, wherein the subject is provided the polysulfide composition by administration to the subject intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostaticaly, intrapleurally, intratracheally, intranasally, intrathecally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, intraocularly, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularally, orally, topically, locally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion, via a catheter, or via a lavage.

### Claim 30 (depends on 16)

The method of claim 16, wherein the subject is provided the polysulfide composition through infusion, inhalation, injection, catheterization, immersion, lavage, perfusion, topical application, absorption, adsorption, or oral administration.

### Claim 31 (depends on 16)

The method of claim 16, further comprising exposing the subject to a controlled temperature and/or pressure environment.

### Claim 32 (depends on 16)

The method of claim 16, further comprising identifying a subject in need of treatment.

### Claim 33 (depends on 16)

The method of claim 16, further comprising evaluating whether the subject is metabolizing the polysulfide composition.

### Claim 34 (depends on 1)

A method for treating a subject with a blood substitute comprising providing to the subject an effective amount of the polysulfide composition of claim 1.

### Claim 35 (depends on 1)

A method of protecting a mammal from suffering cellular damage from a disease or adverse medical condition, comprising providing to the mammal an effective amount of the polysulfide composition of claim 1 prior to the onset or progression of the disease or condition.

### Claim 36 (depends on 35)

The method of claim 35, wherein the disease or adverse medical condition is selected from the group consisting of: hemorrhagic shock, myocardial infarction, acute coronary syndrome, cardiac arrest, neonatal hypoxia/ischemia, ischemic reperfusion injury, unstable angina, post-angioplasty, aneurysm, trauma, and blood loss.

### Claim 37 (depends on 1)

A method for treating hemorrhagic shock in a patient comprising providing to the patient an effective amount of the polysulfide composition of claim 1.

### Claim 38 (depends on 37)

The method of claim 37, wherein the compound does not affect blood pressure by more than 10 mm Hg.

### Claim 39 (depends on 1)

A method of enhancing survivability in a subject comprising providing to the subject an effective amount of the polysulfide composition of claim 1.

### Claim 40 (depends on 39)

The method of claim 39, wherein the subject is suffering from or susceptible to suffering from a disease or adverse medical condition.

### Claim 41 (depends on 40)

The method of claim 40, wherein the disease is thalassemia, sickle cell disease, or cystic fibrosis.
